Stephens Inc. AR Cuts Stock Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

Stephens Inc. AR reduced its position in shares of iShares Biotechnology ETF (NASDAQ:IBBGet Rating) by 11.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,486 shares of the financial services provider’s stock after selling 862 shares during the period. Stephens Inc. AR’s holdings in iShares Biotechnology ETF were worth $759,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of IBB. Synovus Financial Corp grew its position in shares of iShares Biotechnology ETF by 0.7% in the second quarter. Synovus Financial Corp now owns 12,862 shares of the financial services provider’s stock valued at $1,514,000 after purchasing an additional 94 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of iShares Biotechnology ETF in the second quarter valued at approximately $10,069,000. CIBC Private Wealth Group LLC grew its position in shares of iShares Biotechnology ETF by 21.5% in the second quarter. CIBC Private Wealth Group LLC now owns 24,376 shares of the financial services provider’s stock valued at $2,868,000 after purchasing an additional 4,316 shares in the last quarter. Integrated Advisors Network LLC purchased a new stake in shares of iShares Biotechnology ETF in the second quarter valued at approximately $316,000. Finally, Jacobi Capital Management LLC purchased a new stake in shares of iShares Biotechnology ETF in the second quarter valued at approximately $254,000. 58.02% of the stock is currently owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Performance

IBB stock opened at $135.47 on Friday. The business has a 50 day simple moving average of $133.62 and a 200-day simple moving average of $127.53. iShares Biotechnology ETF has a 1 year low of $104.29 and a 1 year high of $138.74.

iShares Biotechnology ETF Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 19th. Investors of record on Wednesday, December 14th were issued a $0.101 dividend. The ex-dividend date of this dividend was Tuesday, December 13th. This is a boost from iShares Biotechnology ETF’s previous quarterly dividend of $0.03. This represents a $0.40 dividend on an annualized basis and a yield of 0.30%.

iShares Biotechnology ETF Company Profile

(Get Rating)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Stories

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.